The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

April 27, 2020 • By Reuters Staff

  • Tweet
  • Email
Print-Friendly Version / Save PDF

(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review.

You Might Also Like
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test

The drug, first approved in 1955, provided no benefit and potentially higher risk of death for patients at U.S. veterans hospitals, according to an analysis that has been submitted for an expert review on Tuesday.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“You hear it both ways,” Pres. Trump told reporters at the White House on Friday after the FDA announcement. “I’m not a doctor. A study has to be done. If it helps, it’s great. If it doesn’t work, don’t do it,” he said.

Trump said he had just spoken with the president of Honduras, who had touted the drug when calling to ask for ventilators. “If it works I think everyone would be in favor of it … check with him, call him.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The FDA said on Friday it was aware of increased use of HCQ and chloroquine through outpatient prescriptions and the malaria drugs could cause abnormal heart rhythms and dangerously rapid heart rate.1

COVID-19, the disease caused by the new coronavirus, has no approved treatment or vaccine. But HCQ has been widely used in an attempt to alter the course of the COVID-19 illness based on anecdotal reports that it may provide some benefit.

There are several randomized trials underway in the U.S. and elsewhere, with the National Institutes of Health last week starting a study to evaluate the safety and the effectiveness of HCQ.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

A research team in Marseilles, France, published data showing that out of 80 mild COVID-19 patients treated with HCQ and antiobiotic azithromycin, 93% had no detectable levels of the virus after eight days.

Doctors have questioned the value of the Marseille study and several papers from China as being too small or poorly designed to offer hard evidence of benefit.

The FDA’s announcement comes a day after the E.U.’s drug regulator warned of side effects of the drugs, urging medical professionals to closely monitor patients on the medicines.

The FDA has allowed healthcare providers to use the drugs for COVID-19 through its emergency use authorization, but has not approved them to treat the disease.

The heart rhythm risks may increase when the medicines are combined with other drugs, such as antibiotic azithromycin, as well as in patients with existing heart and kidney disease, the agency said.2

Pages: 1 2 | Single Page

Filed Under: Drug Updates, Safety Tagged With: coronavirus, COVID-19, FDA, Hydroxychloroquine (HCQ), U.S. Food and Drug Administration (FDA)

You Might Also Like:
  • Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)